Literature DB >> 29704735

Heterophilic interference in specimens yielding false-reactive results on the Abbott 4th generation ARCHITECT HIV Ag/Ab Combo assay.

S Lavoie1, D Caswell2, M J Gill3, K Kadkhoda4, C L Charlton5, P N Levett2, T Hatchette6, R Garceau7, J Maregmen8, T Mazzulli8, R Needle9, K Kadivar1, J Kim10.   

Abstract

BACKGROUND: False-reactivity in HIV-negative specimens has been detected in HIV fourth-generation antigen/antibody or 'combo' assays which are able to detect both anti-HIV-1/HIV-2 antibodies and HIV-1 antigen.
OBJECTIVES: We sought to characterize these specimens and determine the effect of heterophilic interference. STUDY
DESIGN: Specimens previously testing as false-reactive on the Abbott ARCHITECT HIV Ag/Ab combo assay and re-tested on a different (Siemens ADVIA Centaur HIV Ag/Ab) assay. A subset of these specimens were also pre-treated with heterophilic blocking agents and re-tested on the Abbott assay.
RESULTS: Here we report that 95% (252/264) of clinical specimens that were repeatedly reactive on the Abbott ARCHITECT HIV Ag/Ab combo assay (S/Co range, 0.94-678) were negative when re-tested on a different fourth generation HIV combo assay (Siemens ADVIA Centaur HIV Ag/Ab). All 264 samples were subsequently confirmed to be HIV negative. On a small subset (57) of specimens with available volume, pre-treatment with two different reagents (HBT; Heterophilic Blocking Tube, NABT; Non-Specific Blocking Tube) designed to block heterophilic antibody interference either eliminated (HBT) or reduced (NABT) the false reactivity when re-tested on the ARCHITECT HIV Ag/Ab combo assay.
CONCLUSIONS: Our results suggest that the Abbott ARCHITECT HIV Ag/Ab combo assay can be prone to heterophilic antibody interference. Crown
Copyright © 2018. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  4th generation EIA; Abbott ARCHITECT; Combo; False reactive; HIV; Heterophilic

Mesh:

Substances:

Year:  2018        PMID: 29704735     DOI: 10.1016/j.jcv.2018.03.014

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  4 in total

1.  BioRad BioPlex® HIV Ag-Ab assay: Incidence of false positivity in a low-prevalence population and its effects on the current HIV testing algorithm.

Authors:  Jayme Parker; Ana Fiorella Carrasco; Jack Chen
Journal:  J Clin Virol       Date:  2019-04-06       Impact factor: 3.168

2.  False reactive HIV-1 diagnostic test results in an individual from Kenya on multiple testing platforms-A case report.

Authors:  Jew Ochola; Michelle Imbach; Leigh Anne Eller; Mark de Souza; Chiaka Nwoga; June Doryne Otieno; Lucas Otieno; Eric Rono; Edwin Kamau; Trevor A Crowell; John Kevin Owuoth; Christina S Polyak; Valentine Sing'oei
Journal:  IDCases       Date:  2020-12-25

3.  Repeated false reactive ADVIA centaur® and bio-rad Geenius™ HIV tests in a patient self-administering anabolic steroids.

Authors:  Polly Tsybina; Maurice Hennink; Tania Diener; Jessica Minion; Amanda Lang; Stephanie Lavoie; John Kim; Alexander Wong
Journal:  BMC Infect Dis       Date:  2020-01-06       Impact factor: 3.090

4.  The evaluation of low cut-off index values of Elecsys® HIV combi PT assay in predicting false-positive results.

Authors:  Zhuoyun Tang; Yu Gou; Keyi Zhang; Zhongyi Zhao; Yinhao Wei; Dongdong Li; Li Chen; Chuanmin Tao
Journal:  J Clin Lab Anal       Date:  2020-08-25       Impact factor: 2.352

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.